首个获批登革热疫苗CYD-TDV的实施策略:会议报告
登革热疫苗接种可加强全球最常见虫媒病毒病之一的防控。CYD-TDV是首个获批的登革热疫苗,但因仅限9岁及以上血清阳性者使用且需3剂程序,全球推广受限。登革热控制伙伴关系(PDC)召开会议讨论实施策略,新数据支持将初免程序从3剂缩短为2剂、年龄下限从9岁降至6岁、适应证从流行区人群扩展至流行区旅行者,改良2剂方案和多重检测可能改善成本效果,学校为基础的实施策略已开发,但沟通血清阳性限制、可负担性、政府承诺和社区接受度等挑战仍存。
要点
- CYD-TDV仅限9岁及以上血清阳性者使用,需3剂程序,全球推广受限。
- 新数据支持初免程序从3剂缩短为2剂、年龄下限降至6岁、适应证扩展至旅行者。
- 学校为基础的实施策略已开发,改良2剂方案和多重检测可能改善成本效果。
核心结论
- 登革热疫苗接种可加强登革热防控,CYD-TDV实施策略需考虑缩短程序、扩展年龄和适应证及学校为基础等策略。
研究设计与样本
- PDC组织召开关键意见领袖和利益相关者会议,讨论CYD-TDV实施策略。
主要发现
- 新数据支持将初免程序从3剂缩短为2剂、年龄下限从9岁降至6岁、适应证从流行区人群扩展至流行区旅行者。
- 改良2剂方案和多重检测可能改善成本效果。
- 学校为基础的实施策略已开发,可考虑多种实施场景。
关键数值与推荐
- CYD-TDV仅限9岁及以上血清阳性者使用,需3剂程序。
- 新数据支持初免程序从3剂缩短为2剂、年龄下限降至6岁、适应证扩展至流行区旅行者。
临床怎么用
- 可考虑学校为基础的实施策略,使用多种实施场景。
- 需针对关键利益相关者制定量身定制的沟通策略。
局限性
- 关于限制疫苗仅用于血清阳性个体的沟通存在挑战。
- 可负担性、政府承诺和社区接受度因国家而异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dengue vaccination would enhance the control of dengue, one of the most frequent vector-borne viral diseases globally. CYD-TDV is the first dengue vaccine to be licensed, but global uptake has been hampered due to its use being limited to seropositive persons aged 9 years and above, and the need for a 3-dose schedule. The Partnership for Dengue Control (PDC) organized a meeting with key opinion leaders and stakeholders to deliberate on implementation strategies for the use of CYD-TDV. New data have emerged that support the shortening of the primary schedule from a 3 to 2 dose schedule, extending the age range below 9 to 6 years of age, and expanding the indication from endemic populations to also include travelers to endemic areas. Cost-effectiveness may improve with the modified 2-dose regimen and with multiple testing. Strategies to implement a dengue vaccination program have been developed, in particular school-based strategies. A range of delivery scenarios can then be considered, using various settings for each step of the intervention. However, several challenges remain, including communication about limiting the use of this vaccine to seropositive individuals only. Affordability will vary from country to country, as will government commitment and community acceptance. Well-tailored communication strategies that target key stakeholders are expected to make up a significant part of any future dengue vaccination program.
引用
- Fongwen N, Delrieu I, Ham LH, et al. Implementation strategies for the first licensed dengue vaccine: A meeting report. Vaccine. 2021. PMID: 34253416. doi:10.1016/j.vaccine.2021.06.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。